Article

Key clinical point: In patients with type 2 diabetes (T2D) advancing from basal insulin (BI) therapy, a once-daily insulin glargine 100 U/mL and lixisenatide (iGlarLixi) injection regimen showed similar glycemic control to multiple injections with BI plus rapid-acting insulin (RAI), without weight gain.

Major finding: At 6 months, the mean reduction in glycated hemoglobin with iGlarLixi was noninferior to BI+RAI (mean difference [MD] 0.1%; 1-sided P = .0032), with weight gain being significantly lower with iGlarLixi vs BI+RAI (MD −0.8 kg; 2-sided P = .0069). The incidence of hypoglycemia was similar between the treatment groups.

Study details: Findings are from a retrospective study that used propensity score matching to evaluate therapy advancement with iGlarLixi (n = 814) or BI+RAI (n = 814) in patients with T2D on BI therapy.

Disclosures: This study was funded by Sanofi, Paris, France. Some authors declared receiving honoraria for speaking or consulting or research support or serving as advisory board members or speakers for various sources, including Sanofi. Three authors reported being employees of Sanofi.

Source: McCrimmon RJ et al. iGlarLixi versus basal plus rapid-acting insulin in adults with type 2 diabetes advancing from basal insulin therapy: The SoliSimplify real-world study. Diabetes Obes Metab. 2022 (Aug 19). Doi: 10.1111/dom.14844

Key clinical point: In patients with type 2 diabetes (T2D) advancing from basal insulin (BI) therapy, a once-daily insulin glargine 100 U/mL and lixisenatide (iGlarLixi) injection regimen showed similar glycemic control to multiple injections with BI plus rapid-acting insulin (RAI), without weight gain.

Major finding: At 6 months, the mean reduction in glycated hemoglobin with iGlarLixi was noninferior to BI+RAI (mean difference [MD] 0.1%; 1-sided P = .0032), with weight gain being significantly lower with iGlarLixi vs BI+RAI (MD −0.8 kg; 2-sided P = .0069). The incidence of hypoglycemia was similar between the treatment groups.

Study details: Findings are from a retrospective study that used propensity score matching to evaluate therapy advancement with iGlarLixi (n = 814) or BI+RAI (n = 814) in patients with T2D on BI therapy.

Disclosures: This study was funded by Sanofi, Paris, France. Some authors declared receiving honoraria for speaking or consulting or research support or serving as advisory board members or speakers for various sources, including Sanofi. Three authors reported being employees of Sanofi.

Source: McCrimmon RJ et al. iGlarLixi versus basal plus rapid-acting insulin in adults with type 2 diabetes advancing from basal insulin therapy: The SoliSimplify real-world study. Diabetes Obes Metab. 2022 (Aug 19). Doi: 10.1111/dom.14844

Key clinical point: In patients with type 2 diabetes (T2D) advancing from basal insulin (BI) therapy, a once-daily insulin glargine 100 U/mL and lixisenatide (iGlarLixi) injection regimen showed similar glycemic control to multiple injections with BI plus rapid-acting insulin (RAI), without weight gain.

Major finding: At 6 months, the mean reduction in glycated hemoglobin with iGlarLixi was noninferior to BI+RAI (mean difference [MD] 0.1%; 1-sided P = .0032), with weight gain being significantly lower with iGlarLixi vs BI+RAI (MD −0.8 kg; 2-sided P = .0069). The incidence of hypoglycemia was similar between the treatment groups.

Study details: Findings are from a retrospective study that used propensity score matching to evaluate therapy advancement with iGlarLixi (n = 814) or BI+RAI (n = 814) in patients with T2D on BI therapy.

Disclosures: This study was funded by Sanofi, Paris, France. Some authors declared receiving honoraria for speaking or consulting or research support or serving as advisory board members or speakers for various sources, including Sanofi. Three authors reported being employees of Sanofi.

Source: McCrimmon RJ et al. iGlarLixi versus basal plus rapid-acting insulin in adults with type 2 diabetes advancing from basal insulin therapy: The SoliSimplify real-world study. Diabetes Obes Metab. 2022 (Aug 19). Doi: 10.1111/dom.14844

Key clinical point: Dapagliflozin significantly reduced kidney function decline in patients with type 2 diabetes (T2D) and a high cardiovascular disease (CVD) risk across all Kidney Disease: Improving Global Outcomes (KDIGO) risk categories, including those with low baseline end-stage kidney disease (ESKD) risk

Major finding: Dapagliflozin vs placebo led to a significant reduction in kidney-specific composite outcome across all KDIGO risk categories (P_interaction = .97), including those with low baseline kidney disease risk (hazard ratio 0.54; P < .001), with the risk for estimated glomerular filtration rate (eGFR) reductions by ≥30%, ≥40%, ≥50%, and ≥57% being significantly lower with dapagliflozin vs placebo (all P < .05).

Study details: Findings are from a post hoc analysis of the DECLARE-TIMI 58 trial including 16,842 patients with T2D at high CVD risk and low (n = 10,958), moderate (n = 4243), high (n = 1403), and very high (n = 238) ESKD risk according to KDIGO risk categories.

Disclosures: The DECLARE-TIMI 58 trial was funded by AstraZeneca and Bristol-Myers Squibb. Some authors reported receiving research funding, grant support, honoraria, personal fees, or consultancy fees or serving as advisory board members for various resources.

Source: Mosenzon O et al. Dapagliflozin and prevention of kidney disease among patients with type 2 diabetes--Post hoc analyses from the DECLARE-TIMI 58 trial. Diabetes Care. 2022 (Aug 23). Doi: 10.2337/dc22-0382

Key clinical point: Dapagliflozin significantly reduced kidney function decline in patients with type 2 diabetes (T2D) and a high cardiovascular disease (CVD) risk across all Kidney Disease: Improving Global Outcomes (KDIGO) risk categories, including those with low baseline end-stage kidney disease (ESKD) risk

Major finding: Dapagliflozin vs placebo led to a significant reduction in kidney-specific composite outcome across all KDIGO risk categories (P_interaction = .97), including those with low baseline kidney disease risk (hazard ratio 0.54; P < .001), with the risk for estimated glomerular filtration rate (eGFR) reductions by ≥30%, ≥40%, ≥50%, and ≥57% being significantly lower with dapagliflozin vs placebo (all P < .05).

Study details: Findings are from a post hoc analysis of the DECLARE-TIMI 58 trial including 16,842 patients with T2D at high CVD risk and low (n = 10,958), moderate (n = 4243), high (n = 1403), and very high (n = 238) ESKD risk according to KDIGO risk categories.

Disclosures: The DECLARE-TIMI 58 trial was funded by AstraZeneca and Bristol-Myers Squibb. Some authors reported receiving research funding, grant support, honoraria, personal fees, or consultancy fees or serving as advisory board members for various resources.

Source: Mosenzon O et al. Dapagliflozin and prevention of kidney disease among patients with type 2 diabetes--Post hoc analyses from the DECLARE-TIMI 58 trial. Diabetes Care. 2022 (Aug 23). Doi: 10.2337/dc22-0382

Key clinical point: Dapagliflozin significantly reduced kidney function decline in patients with type 2 diabetes (T2D) and a high cardiovascular disease (CVD) risk across all Kidney Disease: Improving Global Outcomes (KDIGO) risk categories, including those with low baseline end-stage kidney disease (ESKD) risk

Major finding: Dapagliflozin vs placebo led to a significant reduction in kidney-specific composite outcome across all KDIGO risk categories (P_interaction = .97), including those with low baseline kidney disease risk (hazard ratio 0.54; P < .001), with the risk for estimated glomerular filtration rate (eGFR) reductions by ≥30%, ≥40%, ≥50%, and ≥57% being significantly lower with dapagliflozin vs placebo (all P < .05).

Study details: Findings are from a post hoc analysis of the DECLARE-TIMI 58 trial including 16,842 patients with T2D at high CVD risk and low (n = 10,958), moderate (n = 4243), high (n = 1403), and very high (n = 238) ESKD risk according to KDIGO risk categories.

Disclosures: The DECLARE-TIMI 58 trial was funded by AstraZeneca and Bristol-Myers Squibb. Some authors reported receiving research funding, grant support, honoraria, personal fees, or consultancy fees or serving as advisory board members for various resources.

Source: Mosenzon O et al. Dapagliflozin and prevention of kidney disease among patients with type 2 diabetes--Post hoc analyses from the DECLARE-TIMI 58 trial. Diabetes Care. 2022 (Aug 23). Doi: 10.2337/dc22-0382

Key clinical point: Patients with type 2 diabetes (T2D) and new-onset atrial fibrillation (AF) are at a higher risk for subsequent atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), chronic kidney disease (CKD), all-cause mortality, and cardiovascular disease (CVD) mortality compared with those with T2D and without new-onset AF.

Major finding: Among patients with T2D, those with vs without incident AF had a higher risk for ASCVD (adjusted hazard ratio [aHR] 1.85; 95% CI 1.59-2.16), HF (aHR 4.40; 95% CI 3.67-5.28), CKD (aHR 1.68; 95% CI 1.41-2.01), all-cause mortality (aHR 2.91; 95% CI 2.53-3.34), and CVD mortality (aHR 3.75; 95% CI 2.93-4.80).

Study details: This study included 16,551 patients with T2D and without CVD and CKD, of which 1394 developed AF during follow-up.

Disclosures: This study did not receive any funding. No potential conflicts of interest were reported.

Source: Geng T et al. Associations of new-onset atrial fibrillation with risks of cardiovascular disease, chronic kidney disease, and mortality among patients with type 2 diabetes. Diabetes Care. 2022 (Aug 19). Doi: 10.2337/dc22-0717

Key clinical point: Patients with type 2 diabetes (T2D) and new-onset atrial fibrillation (AF) are at a higher risk for subsequent atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), chronic kidney disease (CKD), all-cause mortality, and cardiovascular disease (CVD) mortality compared with those with T2D and without new-onset AF.

Major finding: Among patients with T2D, those with vs without incident AF had a higher risk for ASCVD (adjusted hazard ratio [aHR] 1.85; 95% CI 1.59-2.16), HF (aHR 4.40; 95% CI 3.67-5.28), CKD (aHR 1.68; 95% CI 1.41-2.01), all-cause mortality (aHR 2.91; 95% CI 2.53-3.34), and CVD mortality (aHR 3.75; 95% CI 2.93-4.80).

Study details: This study included 16,551 patients with T2D and without CVD and CKD, of which 1394 developed AF during follow-up.

Disclosures: This study did not receive any funding. No potential conflicts of interest were reported.

Source: Geng T et al. Associations of new-onset atrial fibrillation with risks of cardiovascular disease, chronic kidney disease, and mortality among patients with type 2 diabetes. Diabetes Care. 2022 (Aug 19). Doi: 10.2337/dc22-0717

Key clinical point: Patients with type 2 diabetes (T2D) and new-onset atrial fibrillation (AF) are at a higher risk for subsequent atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), chronic kidney disease (CKD), all-cause mortality, and cardiovascular disease (CVD) mortality compared with those with T2D and without new-onset AF.

Major finding: Among patients with T2D, those with vs without incident AF had a higher risk for ASCVD (adjusted hazard ratio [aHR] 1.85; 95% CI 1.59-2.16), HF (aHR 4.40; 95% CI 3.67-5.28), CKD (aHR 1.68; 95% CI 1.41-2.01), all-cause mortality (aHR 2.91; 95% CI 2.53-3.34), and CVD mortality (aHR 3.75; 95% CI 2.93-4.80).

Study details: This study included 16,551 patients with T2D and without CVD and CKD, of which 1394 developed AF during follow-up.

Disclosures: This study did not receive any funding. No potential conflicts of interest were reported.

Source: Geng T et al. Associations of new-onset atrial fibrillation with risks of cardiovascular disease, chronic kidney disease, and mortality among patients with type 2 diabetes. Diabetes Care. 2022 (Aug 19). Doi: 10.2337/dc22-0717

Key clinical point: Canagliflozin reduced not only the risk for the first cardiovascular (CV) events but also subsequent CV events in patients with type 2 diabetes and chronic kidney disease (CKD), with absolute benefits being greater for total CV events.

Major finding: Canagliflozin reduced the risk for the first (hazard ratio 0.74; P < .001) and total (incidence rate ratio 0.71; P < .001) CV events by 26% and 29%, respectively, with the absolute risk difference per 1000 patients treated over 2.5 years being −44 (95% CI −67 to −21) and −73 (95% CI −114 to −33) for the first and total CV events, respectively.

Study details: This was a post hoc analysis of the CREDENCE trial including patients with type 2 diabetes (T2D; glycated hemoglobin 6.5%-12.0%) and CKD who were randomly assigned to receive canagliflozin or placebo.

Disclosures: The CREDENCE trial was sponsored by Janssen Research & Development, LLC. Some authors reported serving as advisory board members, speakers, or consultants, or receiving honoraria, research support, consulting, travel, or scientific presentation fees from various sources, including Janssen.

Source: Li JW et al. Effect of canagliflozin on total cardiovascular burden in patients with diabetes and chronic kidney disease: A post hoc analysis from the CREDENCE trial. J Am Heart Assoc. 2022;11(16):e025045 (Aug 5). Doi: 10.1161/JAHA.121.025045

Key clinical point: Canagliflozin reduced not only the risk for the first cardiovascular (CV) events but also subsequent CV events in patients with type 2 diabetes and chronic kidney disease (CKD), with absolute benefits being greater for total CV events.

Major finding: Canagliflozin reduced the risk for the first (hazard ratio 0.74; P < .001) and total (incidence rate ratio 0.71; P < .001) CV events by 26% and 29%, respectively, with the absolute risk difference per 1000 patients treated over 2.5 years being −44 (95% CI −67 to −21) and −73 (95% CI −114 to −33) for the first and total CV events, respectively.

Study details: This was a post hoc analysis of the CREDENCE trial including patients with type 2 diabetes (T2D; glycated hemoglobin 6.5%-12.0%) and CKD who were randomly assigned to receive canagliflozin or placebo.

Disclosures: The CREDENCE trial was sponsored by Janssen Research & Development, LLC. Some authors reported serving as advisory board members, speakers, or consultants, or receiving honoraria, research support, consulting, travel, or scientific presentation fees from various sources, including Janssen.

Source: Li JW et al. Effect of canagliflozin on total cardiovascular burden in patients with diabetes and chronic kidney disease: A post hoc analysis from the CREDENCE trial. J Am Heart Assoc. 2022;11(16):e025045 (Aug 5). Doi: 10.1161/JAHA.121.025045

Key clinical point: Canagliflozin reduced not only the risk for the first cardiovascular (CV) events but also subsequent CV events in patients with type 2 diabetes and chronic kidney disease (CKD), with absolute benefits being greater for total CV events.

Major finding: Canagliflozin reduced the risk for the first (hazard ratio 0.74; P < .001) and total (incidence rate ratio 0.71; P < .001) CV events by 26% and 29%, respectively, with the absolute risk difference per 1000 patients treated over 2.5 years being −44 (95% CI −67 to −21) and −73 (95% CI −114 to −33) for the first and total CV events, respectively.

Study details: This was a post hoc analysis of the CREDENCE trial including patients with type 2 diabetes (T2D; glycated hemoglobin 6.5%-12.0%) and CKD who were randomly assigned to receive canagliflozin or placebo.

Disclosures: The CREDENCE trial was sponsored by Janssen Research & Development, LLC. Some authors reported serving as advisory board members, speakers, or consultants, or receiving honoraria, research support, consulting, travel, or scientific presentation fees from various sources, including Janssen.

Source: Li JW et al. Effect of canagliflozin on total cardiovascular burden in patients with diabetes and chronic kidney disease: A post hoc analysis from the CREDENCE trial. J Am Heart Assoc. 2022;11(16):e025045 (Aug 5). Doi: 10.1161/JAHA.121.025045

Key clinical point: Statin exposure reduces the risk for and improves the prognosis of gastric cancer.

Major finding: The statin-exposed vs -nonexposed population showed a significantly reduced incidence (odds ratio [OR] 0.78; P < .001) and improved prognosis (OR 0.78; P = .002) of gastric cancer.

Study details: This was a meta-analysis of 19 studies that analyzed the correlation between statin exposure and the occurrence and progression of gastric cancer.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Lou D et al. Association between statins' exposure with incidence and prognosis of gastric cancer: An updated meta-analysis. Expert Rev Clin Pharmacol. 2022; 1-12 (Aug 15). Doi: 10.1080/17512433.2022.2112178

Key clinical point: Statin exposure reduces the risk for and improves the prognosis of gastric cancer.

Major finding: The statin-exposed vs -nonexposed population showed a significantly reduced incidence (odds ratio [OR] 0.78; P < .001) and improved prognosis (OR 0.78; P = .002) of gastric cancer.

Study details: This was a meta-analysis of 19 studies that analyzed the correlation between statin exposure and the occurrence and progression of gastric cancer.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Lou D et al. Association between statins' exposure with incidence and prognosis of gastric cancer: An updated meta-analysis. Expert Rev Clin Pharmacol. 2022; 1-12 (Aug 15). Doi: 10.1080/17512433.2022.2112178

Key clinical point: Statin exposure reduces the risk for and improves the prognosis of gastric cancer.

Major finding: The statin-exposed vs -nonexposed population showed a significantly reduced incidence (odds ratio [OR] 0.78; P < .001) and improved prognosis (OR 0.78; P = .002) of gastric cancer.

Study details: This was a meta-analysis of 19 studies that analyzed the correlation between statin exposure and the occurrence and progression of gastric cancer.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Lou D et al. Association between statins' exposure with incidence and prognosis of gastric cancer: An updated meta-analysis. Expert Rev Clin Pharmacol. 2022; 1-12 (Aug 15). Doi: 10.1080/17512433.2022.2112178

Key clinical point: The presence of myosteatosis along with increased systemic inflammatory response markers, such as neutrophil-to-lymphocyte ratio (NLR), serves as an independent prognostic indicator in patients with resectable gastric cancer.

Major finding: Co-occurrence of myosteatosis and an NLR of > 2.3 was significantly associated with worse disease-free survival (hazard ratio [HR] 2.77; P = .001) and overall survival (HR 3.31; P < .001).

Study details: This single-center retrospective observational study included 280 patients with gastric cancer who underwent total or partial gastrectomy with curative intent.

Disclosures: This study was funded by Fundação de Amparo à Pesquisa do Estado de São Paulo and Conselho Nacional de Desenvolvimento Científico e Tecnológico, Brazil. The authors declared no conflicts of interest.

Source: Lascala F et al. Prognostic value of myosteatosis and systemic inflammation in patients with resectable gastric cancer: A retrospective study. Eur J Clin Nutr. 2022 (Sep 8). Doi: 10.1038/s41430-022-01201-7

Key clinical point: The presence of myosteatosis along with increased systemic inflammatory response markers, such as neutrophil-to-lymphocyte ratio (NLR), serves as an independent prognostic indicator in patients with resectable gastric cancer.

Major finding: Co-occurrence of myosteatosis and an NLR of > 2.3 was significantly associated with worse disease-free survival (hazard ratio [HR] 2.77; P = .001) and overall survival (HR 3.31; P < .001).

Study details: This single-center retrospective observational study included 280 patients with gastric cancer who underwent total or partial gastrectomy with curative intent.

Disclosures: This study was funded by Fundação de Amparo à Pesquisa do Estado de São Paulo and Conselho Nacional de Desenvolvimento Científico e Tecnológico, Brazil. The authors declared no conflicts of interest.

Source: Lascala F et al. Prognostic value of myosteatosis and systemic inflammation in patients with resectable gastric cancer: A retrospective study. Eur J Clin Nutr. 2022 (Sep 8). Doi: 10.1038/s41430-022-01201-7

Key clinical point: The presence of myosteatosis along with increased systemic inflammatory response markers, such as neutrophil-to-lymphocyte ratio (NLR), serves as an independent prognostic indicator in patients with resectable gastric cancer.

Major finding: Co-occurrence of myosteatosis and an NLR of > 2.3 was significantly associated with worse disease-free survival (hazard ratio [HR] 2.77; P = .001) and overall survival (HR 3.31; P < .001).

Study details: This single-center retrospective observational study included 280 patients with gastric cancer who underwent total or partial gastrectomy with curative intent.

Disclosures: This study was funded by Fundação de Amparo à Pesquisa do Estado de São Paulo and Conselho Nacional de Desenvolvimento Científico e Tecnológico, Brazil. The authors declared no conflicts of interest.

Source: Lascala F et al. Prognostic value of myosteatosis and systemic inflammation in patients with resectable gastric cancer: A retrospective study. Eur J Clin Nutr. 2022 (Sep 8). Doi: 10.1038/s41430-022-01201-7

Key clinical point: A shorter gastric observation time during index esophagogastroduodenoscopy (EGD; preceding gastric cancer diagnosis) serves as an important predictor of the occurrence of interval advanced gastric cancer.

Major finding: A shorter observation time (<3 min; adjusted odds ratio 2.27;  95% CI 1.20-4.30) at preceding endoscopy was independently associated with an increased risk for interval advanced gastric cancer.

Study details: Findings are from a retrospective nested case-control study that included 1257 patients diagnosed with gastric cancer within 6-36 months of “cancer-negative” index EGD, of which 102 patients had advanced gastric cancer.

Disclosures: This study was supported by the Research Fund of the Korean Society of Gastroenterology and a National Research Foundation of Korea grant funded by the Korea government. The authors declared no conflicts of interest.

Source: Kim TJ et al. Interval advanced gastric cancer after negative endoscopy. Clin Gastroenterol Hepatol. 2022 (Sep 5). Doi: 10.1016/j.cgh.2022.08.027

Key clinical point: A shorter gastric observation time during index esophagogastroduodenoscopy (EGD; preceding gastric cancer diagnosis) serves as an important predictor of the occurrence of interval advanced gastric cancer.

Major finding: A shorter observation time (<3 min; adjusted odds ratio 2.27;  95% CI 1.20-4.30) at preceding endoscopy was independently associated with an increased risk for interval advanced gastric cancer.

Study details: Findings are from a retrospective nested case-control study that included 1257 patients diagnosed with gastric cancer within 6-36 months of “cancer-negative” index EGD, of which 102 patients had advanced gastric cancer.

Disclosures: This study was supported by the Research Fund of the Korean Society of Gastroenterology and a National Research Foundation of Korea grant funded by the Korea government. The authors declared no conflicts of interest.

Source: Kim TJ et al. Interval advanced gastric cancer after negative endoscopy. Clin Gastroenterol Hepatol. 2022 (Sep 5). Doi: 10.1016/j.cgh.2022.08.027

Key clinical point: A shorter gastric observation time during index esophagogastroduodenoscopy (EGD; preceding gastric cancer diagnosis) serves as an important predictor of the occurrence of interval advanced gastric cancer.

Major finding: A shorter observation time (<3 min; adjusted odds ratio 2.27;  95% CI 1.20-4.30) at preceding endoscopy was independently associated with an increased risk for interval advanced gastric cancer.

Study details: Findings are from a retrospective nested case-control study that included 1257 patients diagnosed with gastric cancer within 6-36 months of “cancer-negative” index EGD, of which 102 patients had advanced gastric cancer.

Disclosures: This study was supported by the Research Fund of the Korean Society of Gastroenterology and a National Research Foundation of Korea grant funded by the Korea government. The authors declared no conflicts of interest.

Source: Kim TJ et al. Interval advanced gastric cancer after negative endoscopy. Clin Gastroenterol Hepatol. 2022 (Sep 5). Doi: 10.1016/j.cgh.2022.08.027

Key clinical point: Laparoscopic proximal gastrectomy (LPG) and laparoscopic total gastrectomy (LTG) lead to similar long-term outcomes and postoperative complications in patients with upper third clinical stage I gastric cancer.

Major finding: Patients who underwent LPG and LTG showed no significant difference in the 3-year overall survival (92.6% and 92.3%, respectively; P = .74), recurrence-free survival (both 85.3%; P = .72), early complication (eg, surgical site infection; P = .31), and late complication (eg, anastomotic stenosis; P = .31) rates.

Study details: This retrospective study propensity score-matched patients with upper third clinical stage I gastric cancer who underwent LTG (n = 28) and those who underwent LPG (n = 28).

Disclosures: No source of funding was reported. The authors declared no conflicts of interest.

Source: Yamamoto M et al. Laparoscopic proximal gastrectomy with novel valvuloplastic esophagogastrostomy vs laparoscopic total gastrectomy for stage I gastric cancer: A propensity score matching analysis. J Gastrointest Surg. 2022 (Aug 29). Doi: 10.1007/s11605-022-05404-y

Key clinical point: Laparoscopic proximal gastrectomy (LPG) and laparoscopic total gastrectomy (LTG) lead to similar long-term outcomes and postoperative complications in patients with upper third clinical stage I gastric cancer.

Major finding: Patients who underwent LPG and LTG showed no significant difference in the 3-year overall survival (92.6% and 92.3%, respectively; P = .74), recurrence-free survival (both 85.3%; P = .72), early complication (eg, surgical site infection; P = .31), and late complication (eg, anastomotic stenosis; P = .31) rates.

Study details: This retrospective study propensity score-matched patients with upper third clinical stage I gastric cancer who underwent LTG (n = 28) and those who underwent LPG (n = 28).

Disclosures: No source of funding was reported. The authors declared no conflicts of interest.

Source: Yamamoto M et al. Laparoscopic proximal gastrectomy with novel valvuloplastic esophagogastrostomy vs laparoscopic total gastrectomy for stage I gastric cancer: A propensity score matching analysis. J Gastrointest Surg. 2022 (Aug 29). Doi: 10.1007/s11605-022-05404-y

Key clinical point: Laparoscopic proximal gastrectomy (LPG) and laparoscopic total gastrectomy (LTG) lead to similar long-term outcomes and postoperative complications in patients with upper third clinical stage I gastric cancer.

Major finding: Patients who underwent LPG and LTG showed no significant difference in the 3-year overall survival (92.6% and 92.3%, respectively; P = .74), recurrence-free survival (both 85.3%; P = .72), early complication (eg, surgical site infection; P = .31), and late complication (eg, anastomotic stenosis; P = .31) rates.

Study details: This retrospective study propensity score-matched patients with upper third clinical stage I gastric cancer who underwent LTG (n = 28) and those who underwent LPG (n = 28).

Disclosures: No source of funding was reported. The authors declared no conflicts of interest.

Source: Yamamoto M et al. Laparoscopic proximal gastrectomy with novel valvuloplastic esophagogastrostomy vs laparoscopic total gastrectomy for stage I gastric cancer: A propensity score matching analysis. J Gastrointest Surg. 2022 (Aug 29). Doi: 10.1007/s11605-022-05404-y

Key clinical point: Modern perioperative chemotherapy (PC) combined with minimally invasive surgery (MIS) improves lymph node yield and long-term survival without affecting postoperative morbidity in operable gastric cancer.

Major finding: Compared with surgery in 2005-2010, that in 2016-2021 and 2011-2015 was associated with adjusted hazard ratios (95% CI) for overall 3-year mortality of 0.37 (0.20-0.68) and 1.02 (0.63-1.66), respectively. Surgery in 2016-2021 vs 2005-2010 led to significantly increased median lymph node yield (23 vs 17; P < .001) but similar major complication rates (15.5% vs 12.3%; P = .736).

Study details: This real-world retrospective study included 181 patients with gastric or esophagogastric junction adenocarcinoma who underwent curative intent surgery in years 2005-2010 (open surgery+adjuvant therapy; n = 65), 2011-2015 (PC+MIS adopted; n = 58), and 2016-2021 (PC+MIS standard practice; n = 58).

Disclosures: This study was sponsored by the Instrumentarium Science Foundation, Helsinki, Finland, among others. The authors declared no conflicts of interest.

Source: Junttila A et al. Implementation of multimodality therapy and minimally invasive surgery: Short- and long-term outcomes of gastric cancer surgery in medium-volume center. J Gastrointest Surg. 2022 (Aug 24). Doi: 10.1007/s11605-022-05437-3

Key clinical point: Modern perioperative chemotherapy (PC) combined with minimally invasive surgery (MIS) improves lymph node yield and long-term survival without affecting postoperative morbidity in operable gastric cancer.

Major finding: Compared with surgery in 2005-2010, that in 2016-2021 and 2011-2015 was associated with adjusted hazard ratios (95% CI) for overall 3-year mortality of 0.37 (0.20-0.68) and 1.02 (0.63-1.66), respectively. Surgery in 2016-2021 vs 2005-2010 led to significantly increased median lymph node yield (23 vs 17; P < .001) but similar major complication rates (15.5% vs 12.3%; P = .736).

Study details: This real-world retrospective study included 181 patients with gastric or esophagogastric junction adenocarcinoma who underwent curative intent surgery in years 2005-2010 (open surgery+adjuvant therapy; n = 65), 2011-2015 (PC+MIS adopted; n = 58), and 2016-2021 (PC+MIS standard practice; n = 58).

Disclosures: This study was sponsored by the Instrumentarium Science Foundation, Helsinki, Finland, among others. The authors declared no conflicts of interest.

Source: Junttila A et al. Implementation of multimodality therapy and minimally invasive surgery: Short- and long-term outcomes of gastric cancer surgery in medium-volume center. J Gastrointest Surg. 2022 (Aug 24). Doi: 10.1007/s11605-022-05437-3

Key clinical point: Modern perioperative chemotherapy (PC) combined with minimally invasive surgery (MIS) improves lymph node yield and long-term survival without affecting postoperative morbidity in operable gastric cancer.

Major finding: Compared with surgery in 2005-2010, that in 2016-2021 and 2011-2015 was associated with adjusted hazard ratios (95% CI) for overall 3-year mortality of 0.37 (0.20-0.68) and 1.02 (0.63-1.66), respectively. Surgery in 2016-2021 vs 2005-2010 led to significantly increased median lymph node yield (23 vs 17; P < .001) but similar major complication rates (15.5% vs 12.3%; P = .736).

Study details: This real-world retrospective study included 181 patients with gastric or esophagogastric junction adenocarcinoma who underwent curative intent surgery in years 2005-2010 (open surgery+adjuvant therapy; n = 65), 2011-2015 (PC+MIS adopted; n = 58), and 2016-2021 (PC+MIS standard practice; n = 58).

Disclosures: This study was sponsored by the Instrumentarium Science Foundation, Helsinki, Finland, among others. The authors declared no conflicts of interest.

Source: Junttila A et al. Implementation of multimodality therapy and minimally invasive surgery: Short- and long-term outcomes of gastric cancer surgery in medium-volume center. J Gastrointest Surg. 2022 (Aug 24). Doi: 10.1007/s11605-022-05437-3

Key clinical point: Lymph node ratio (LNR) may serve as an independent prognosis predictor in patients with locally advanced gastric cancer (LAGC) after neoadjuvant chemotherapy (NACT).

Major finding: Patients with a low vs high LNR had significantly longer 3-year overall survival (OS; 81.9% vs 18.5%; P < .001) and progression-free survival (PFS; 72.6% vs 13.5%; P < .001) rates. Multivariate analysis revealed LNR to be the only independent predictive factor for both OS (adjusted hazard ratio [aHR] 6.90; P < .001) and PFS (aHR 5.58; P < .001).

Study details: This retrospective study included 148 patients with LAGC who underwent NACT and radical gastrectomy and were categorized to have a low (≤30%; n = 103) or high (>30%; n = 45) LNR.

Disclosures: This study was sponsored by the National Natural Science Foundation of China and the Natural Science Foundation of Hubei Province. The authors declared no conflicts of interest.

Source: Jiang Q et al. Lymph node ratio is a prospective prognostic indicator for locally advanced gastric cancer patients after neoadjuvant chemotherapy. World J Surg Oncol. 2022;20(1):261 (Aug 17). Doi: 10.1186/s12957-022-02725-9

Key clinical point: Lymph node ratio (LNR) may serve as an independent prognosis predictor in patients with locally advanced gastric cancer (LAGC) after neoadjuvant chemotherapy (NACT).

Major finding: Patients with a low vs high LNR had significantly longer 3-year overall survival (OS; 81.9% vs 18.5%; P < .001) and progression-free survival (PFS; 72.6% vs 13.5%; P < .001) rates. Multivariate analysis revealed LNR to be the only independent predictive factor for both OS (adjusted hazard ratio [aHR] 6.90; P < .001) and PFS (aHR 5.58; P < .001).

Study details: This retrospective study included 148 patients with LAGC who underwent NACT and radical gastrectomy and were categorized to have a low (≤30%; n = 103) or high (>30%; n = 45) LNR.

Disclosures: This study was sponsored by the National Natural Science Foundation of China and the Natural Science Foundation of Hubei Province. The authors declared no conflicts of interest.

Source: Jiang Q et al. Lymph node ratio is a prospective prognostic indicator for locally advanced gastric cancer patients after neoadjuvant chemotherapy. World J Surg Oncol. 2022;20(1):261 (Aug 17). Doi: 10.1186/s12957-022-02725-9

Key clinical point: Lymph node ratio (LNR) may serve as an independent prognosis predictor in patients with locally advanced gastric cancer (LAGC) after neoadjuvant chemotherapy (NACT).

Major finding: Patients with a low vs high LNR had significantly longer 3-year overall survival (OS; 81.9% vs 18.5%; P < .001) and progression-free survival (PFS; 72.6% vs 13.5%; P < .001) rates. Multivariate analysis revealed LNR to be the only independent predictive factor for both OS (adjusted hazard ratio [aHR] 6.90; P < .001) and PFS (aHR 5.58; P < .001).

Study details: This retrospective study included 148 patients with LAGC who underwent NACT and radical gastrectomy and were categorized to have a low (≤30%; n = 103) or high (>30%; n = 45) LNR.

Disclosures: This study was sponsored by the National Natural Science Foundation of China and the Natural Science Foundation of Hubei Province. The authors declared no conflicts of interest.

Source: Jiang Q et al. Lymph node ratio is a prospective prognostic indicator for locally advanced gastric cancer patients after neoadjuvant chemotherapy. World J Surg Oncol. 2022;20(1):261 (Aug 17). Doi: 10.1186/s12957-022-02725-9